Search Results - "Dalchau, K."

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma by Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., lwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I.

“…Background Nab-paclitaxel plus gemcitabine (nabP+gemcitabine) offers modest survival gains for patients with metastatic pancreatic ductal adenocarcinoma…”
Get full text

747TiPSCHEDULING NAB-PACLITAXEL WITH GEMCITABINE (SIEGE): RANDOMISED PHASE II TRIAL TO INVESTIGATE TWO DIFFERENT SCHEDULES OF NAB-PACLITAXEL (ABX) COMBINED WITH GEMCITABINE (GEM) AS FIRST LINE TREATMENT FOR METASTATIC PANCREATIC ADENOCARCINOMA (PDAC) by Corrie, P., Qian, W., Jodrell, D.I., Lao-Sirieix, S., Whittaker, P., Gopinathan, A., Chhabra, A., Dalchau, K., Basu, B., Hardy, R., Valle, J.W.

“…Abstract Background: PDAC carries a poor prognosis. Recently ABX combined with GEM was shown to improve overall survival compared with standard single agent…”
Get full text

Scheduling Nab-Paclitaxel with Gemcitabine (Siege): Randomised Phase Ii Trial to Investigate Two Different Schedules of Nab-Paclitaxel (Abx) Combined with Gemcitabine (Gem) As First Line Treatment for Metastatic Pancreatic Adenocarcinoma (Pdac) by Corrie, P., Qian, W., Jodrell, D.I., Lao-Sirieix, S., Whittaker, P., Gopinathan, A., Chhabra, A., Dalchau, K., Basu, B., Hardy, R., Valle, J.W.

Get full text